Follow-up study for children with newly diagnosed nephrotic syndrome
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study follows children in France who developed idiopathic nephrotic syndrome after 2018, to learn how the condition behaves over time. It may help doctors improve future care by tracking symptoms and outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be under 18 years old
- Have idiopathic nephrotic syndrome that started after January 1, 2018
- Have been seen by a pediatric kidney specialist (a member of the Society of Pediatric Nephrology) at least once
- Live in France
- Have signed permission from parents (and your agreement if you’re old enough)
- Be covered by France’s social security system
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at children’s experiences and understanding of nephrotic syndrome using questionnaires. It aims to learn what helps families and children, which could improve care over time.
This study is looking for children newly diagnosed with idiopathic nephrotic syndrome (a kidney condition that causes swelling and protein in the urine) who have not yet been treated. Researchers will study their blood and genes to find better ways to predict how the disease will progress and which treatments might work best.
This study tracks children with nephrotic syndrome whose kidney disease does not respond to usual treatments. It aims to collect information and samples to better understand resistant forms of the condition.
This trial collects medical data and blood/urine samples from patients with minimal change disease or focal segmental glomerulosclerosis (FSGS) to better understand how the immune system damages kidney cells.
This trial studies whether rituximab alone can help children with new-onset idiopathic nephrotic syndrome. It compares the treatment approach in order to see if it improves kidney recovery and reduces disease activity.
This trial tests if dupilumab can help children with nephrotic syndrome who still have relapses despite standard treatments. It aims to find a better way to control the disease and reduce steroid side effects.
Hear when a new Idiopathic Nephrotic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.